SHANGHAI, March 6 (Reuters) - Sciwind Biosciences' GLP-1 injection ecnoglutide has been approved for use in China for chronic weight management in adults who are overweight or obese, the company said in a statement on its website Friday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.